Skip to content

Preliminary clinical studies of stem cells therapy for retinal degeneration diseases

Preliminary clinical studies of stem cells therapy for retinal degeneration diseases

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OCH-14005060
Enrollment
Unknown
Registered
2014-07-12
Start date
2014-08-05
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retinal degeneration diseases

Interventions

One cohort:stem cells therapy

Sponsors

Southwest Hospital, Third Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patient has signed informed consent for retinal transplantation and is willing to return for follow-up visits; 2. Age range 18 to 65 years,gender unlimited; 3. Patients with at least one eye (monocular) or both eyes suffering from impaired vision caused by retinal degeneration diseases; 4. Use the early treatment diabetic retinopathy (ETDRs) eye chart in 4 meters distance detection, best corrected visual acuity scores between 19 and 73 letter, including 19 and 73 (or the equivalent of about Snellen eyesight from 20/400 to 20/40).

Exclusion criteria

Exclusion criteria: 1. Patient has medical problems that have a high risk of general anesthesia, such as metabolic, cadiovascular, hematopoietic or psychological system disorders; 2. Women in menstruation, pregnancy, perinatal prtiod and baby nursing periods; 3. Any significant ocular disease that has compromised or could compromise vision in the study eye and confound analysis of the primary outcome; 4. Patient who has a history of corneal leukoma, cataract, uveitis, Coat's disease, diabetic retinopathy, glaucoma, or vitreous opacities that prevents visualization of the posterior pole; 5. Participating in another ophthalmic clinical trial or use of any other investigational new drugs within 3 months before the start of study treatment; 6. Intraocular surgery within the last 3 months.

Design outcomes

Primary

MeasureTime frame
Early treatment of diabetic retinopathy eye chart (ETDRs);Fluorescein angiography;Static perimetry;Optical coherent tomography (OCT);Flash electroretinogram (FERG);Flash Visual Evoked Potentials (FVEP);mutifocal electroretinogram (MFERG);Pupillary light reflex;

Contacts

Public ContactYin Zhengqin
qinzyin@aliyun.com+86 023 68754401

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026